Table 1 Gene profile of PBMCs of MS patients and normal subjects
From: SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients
Gene | No treatment | IL-4 treatment | ||||
---|---|---|---|---|---|---|
Normal subjects | MS patients | SHP-1 siRNA | Normal subjects | MS patients | SHP-1 SiRNA | |
SHP-1 | 1.0±0.1 | 0.4±0.10* | 0.1±0.1* | 1.1±0.1 | 0.3±0.2† | 0.1±0.1† |
IL-4 | 1.0±0.1 | 3.2±0.8* | 2.8±0.6* | 1.8±0.2 | 4.1±0.5† | 3.9±1.0† |
IL-4-rα | 1.0±0.1 | 0.8±0.2 | 1.3±0.3 | 1.2±0.1 | 1.01±0.2 | 1.1±0.4 |
CCL17 | 1.0±0.2 | 5.9±1.4* | 2.8±0.5* | 2.8±0.1 | 21.5±6.3† | 6.9±1.3† |
CCL11 | 1.0±0.3 | 2.2±0.4* | 7.2±2.7* | 2.9±0.7 | 6.4±2.1† | 16.8±7.2† |
CCR4 | 1.0±0.2 | 2.4±0.6* | 1.3±0.4 | 1.6±0.2 | 2.8±0.5† | 1.4±0.3 |
CCR8 | 1.0±0.2 | 1.5±0.3 | 1.3±0.5 | 1.2±0.1 | 1.8±0.2 | 1.5±0.2 |
ADAM8 | 1.0±0.3 | 3.4±0.4* | 2.4±1.2* | 2.6±0.6 | 4.8±0.6† | 6.4±3.0† |
LTα | 1.0±0.2 | 3.7±1.2* | 2.8±1.0* | 1.8±0.2 | 6.2±1.6† | 3.1±1.0 |
Arginase I | 1.0±0.2 | 2.4±0.6* | 5.1±2.1* | 2.8±0.3 | 5.2±1.6† | 10.1±5.7† |
IFN-γ | 1.0±0.2 | 1.2±0.4 | 1.3±0.4 | 0.8±0.2 | 0.9±0.2 | 1.1±0.2 |
IP-10 | 1.0±0.3 | 3.0±0.6* | 1.9±0.4 | 0.7±0.4 | 2.9±0.5† | 1.8±0.5 |
CXCR3 | 1.0±0.2 | 0.7±0.2 | 0.8+0.4 | 1.1+0.3 | 0.9+0.4 | 0.7+0.5 |
MCP-1 | 1.0±0.3 | 0.8±0.2 | 0.7±0.3 | 0.7±0.3 | 1.0±0.5 | 0.6±0.2 |
GAPDH | 1.0±0.2 | 0.9±0.2 | 0.8±0.2 | 0.8±0.2 | 0.9±0.1 | 0.9±0.1 |